Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis

International Urology and Nephrology

Volumn 47, Issue 5, 2015, Pages 815-822

  Tian, Mao Lu ^a   Shen, Yan ^a   Sun, Zhao Lin ^a   Zha, Yan ^a  

^a GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Diabetic nephropathy; Pentoxifylline; Randomized controlled trails

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR;

ALBUMINURIA; BLOOD; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DRUG COMBINATION; HUMAN; META ANALYSIS; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CREATININE; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84937759987     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-015-0968-2     Document Type: Review

References (35)

1. Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370(16):1514–1523
2. Haffner SM, Lehto S, Rönnemaa T et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234
3. Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Socm Nephrol 24(2):302–308
4. Parving HH (1996) Initiation and progression of diabetic nephropathy. N Engl J Med 335(22):1682–1683
5. Kdigo BP (2012) Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2:337–414
6. American Diabetes Association (2014) Standards of medical care in diabetes 2014. Diab Care 37(Suppl 1):S14–S80
7. Perkins BA, Ficociello LH, Silva KH et al (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348(23):2285–2293
8. National Kidney Foundation (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886
9. Parving HH, Brenner BM, Investigators ALTITUDE et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367(23):2204–2213
10. Fried LF, Emanuele N, Investigators VANEPHRON-D et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369(20):1892–1903
11. De Sanctis MT, Cesarone MR, Belcaro G et al (2002) Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial–walking distance and microcirculation. Angiology 53(Suppl 1):S7–S12
12. Abdel-Salam OM, Baiuomy AR, El-Shenawy SM et al (2003) The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res 47(4):331–340
13. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M et al (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7(6):327–340
14. Navarro JF, Mora C, Maca M et al (2003) Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42(1):53–61
15. Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34(1):50–97
16. Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33(3):458–463
17. McCormick BB, Sydor A, Akbari A et al (2008) The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 52(3):454–463
18. Shan D, Wu HM, Yuan QY et al (2012) Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev 15(2):CD006800
19. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
20. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
21. Harmankaya O, Seber S, Yilmaz M (2003) Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25(3):465–470
22. Navarro JF, Mora C, Muros M et al (2003) Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am J Kidney Dis 42(2):264–270
23. Navarro JF, Mora C, Muros M et al (2005) Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 16(7):2119–2126
24. Roozbeh J, Banihashemi MA, Ghezlou M et al (2010) Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail 32(2):172–178
25. Oliaei F, Hushmand S, Khafri S et al (2011) Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients. Caspian J Intern Med 2(4):309–313
26. Jin-Lei LV, Liu-Qing LV, Yi SHAO et al (2012) Valsartan combined with pentoxifylline in treatment of diabetic retinopathy and diabetic Nephropathy. Rec Adv Ophthalmol 32(10):945–948
27. Ghorbani A, Omidvar B, Beladi-Mousavi SS et al (2012) The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 32(6):790–796
28. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M et al (2015) Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol 26(1):220–229
29. Perkins RM, Aboudara MC, Uy AL et al (2009) Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 53(4):606–616
30. Goicoechea M, García de Vinuesa S, Quiroga B et al (2012) Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol 25(6):969–975
31. Dávila-Esqueda ME, Martínez-Morales F (2004) Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat. Exp Diabesity Res 5(4):245–251
32. Chen YM, Lin SL, Chiang WC et al (2006) Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 69:1410–1415
33. Dalla Vestra M, Mussap M, Gallina P et al (2005) Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 16(Suppl 1):S78–S82
34. Ortiz A, González-Cuadrado R, Sharma M et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34
35. Doherty GM, Jensen JC, Alexander HR et al (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110(2):192–198